GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellerophon Therapeutics Inc (OTCPK:BLPH) » Definitions » Cyclically Adjusted PB Ratio

Bellerophon Therapeutics (Bellerophon Therapeutics) Cyclically Adjusted PB Ratio : 0.00 (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Bellerophon Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-05-14), Bellerophon Therapeutics's current share price is $0.0563. Bellerophon Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $13.03. Bellerophon Therapeutics's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Bellerophon Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Bellerophon Therapeutics's highest Cyclically Adjusted PB Ratio was 0.87. The lowest was 0.01. And the median was 0.05.

BLPH's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.79
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Bellerophon Therapeutics's adjusted book value per share data for the three months ended in Sep. 2023 was $0.304. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $13.03 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Bellerophon Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Bellerophon Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellerophon Therapeutics Cyclically Adjusted PB Ratio Chart

Bellerophon Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bellerophon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.62 0.05 0.03

Competitive Comparison of Bellerophon Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Bellerophon Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellerophon Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellerophon Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Bellerophon Therapeutics's Cyclically Adjusted PB Ratio falls into.



Bellerophon Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Bellerophon Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.0563/13.03
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bellerophon Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Bellerophon Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.304/129.8595*129.8595
=0.304

Current CPI (Sep. 2023) = 129.8595.

Bellerophon Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 -18.299 98.326 -24.168
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 44.224 100.428 57.184
201412 28.899 99.070 37.880
201503 72.515 99.621 94.526
201506 59.503 100.684 76.745
201509 46.821 100.392 60.564
201512 34.654 99.792 45.095
201603 26.603 100.470 34.385
201606 21.621 101.688 27.611
201609 18.607 101.861 23.722
201612 8.513 101.863 10.853
201703 0.364 102.862 0.460
201706 -0.335 103.349 -0.421
201709 4.278 104.136 5.335
201712 -0.684 104.011 -0.854
201803 0.580 105.290 0.715
201806 -2.019 106.317 -2.466
201809 1.004 106.507 1.224
201812 0.986 105.998 1.208
201903 2.243 107.251 2.716
201906 2.495 108.070 2.998
201909 1.600 108.329 1.918
201912 0.784 108.420 0.939
202003 0.442 108.902 0.527
202006 5.622 108.767 6.712
202009 4.830 109.815 5.712
202012 4.030 109.897 4.762
202103 3.485 111.754 4.050
202106 3.166 114.631 3.587
202109 2.713 115.734 3.044
202112 2.265 117.630 2.500
202203 1.694 121.301 1.814
202206 1.286 125.017 1.336
202209 0.778 125.227 0.807
202212 0.263 125.222 0.273
202303 1.015 127.348 1.035
202306 0.460 128.729 0.464
202309 0.304 129.860 0.304

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Bellerophon Therapeutics  (OTCPK:BLPH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Bellerophon Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Bellerophon Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellerophon Therapeutics (Bellerophon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
184 Liberty Corner Road, Suite 302, Warren, NJ, USA, 07059
Bellerophon Therapeutics Inc is a clinical-stage therapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company's products are aimed at the treatment of different kinds of pulmonary hypertension.
Executives
Puissance Life Science Opportunities Fund Vi 10 percent owner 950 THIRD AVENUE, FL 25, NEW YORK NY 10022
Naseem Amin director 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Mary Ann Cloyd director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Theodore T Wang director C/O PUISSANCE CAPITAL MANAGEMENT LP, 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Scott P Bruder director C/O BELLEROPHON THERAPEUTICS, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Crispin Teufel director 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Puissance Capital Fund (gp) Llc 10 percent owner 950 THIRD AVENUE, 25TH FLOOR, NEW YORK NY 10022
Parag Suresh Shah officer: VP of Business Operations C/O BELLEROPHON THERAPEUTICS, INC., 184 LIBERTY CORNER ROAD, SUITE 302, NEW JERSEY NJ 07059
Martin Dekker officer: See Remarks 53 FRONTAGE ROAD, SUITE 301, PERRYVILLE III CORPORATE PARK, HAMPTON NJ 08827
Peter Fernandes officer: See Remarks PERRYVILLE III CORPORATE PARK, 53 FRONTAGE ROAD, SUITE 301, HAMPTON NJ 08827
Bobae Kim officer: VP Reg. Affairs & Quality 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Nicholas Laccona officer: Controller, (PFO & PAO) 184 LIBERTY CORNER ROAD, SUITE 302, WARREN NJ 07059
Steven B Klinsky 10 percent owner C/O NEW MOUNTAIN CAPITAL, L.L.C., 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Capital, L.l.c. 10 percent owner 1633 BROADWAY, 48TH FLOOR, NEW YORK NY 10019
New Mountain Investments Ii, Llc 10 percent owner 787 SEVENTH AVENUE, 49TH FLOOR, NEW YORK NY 10019

Bellerophon Therapeutics (Bellerophon Therapeutics) Headlines